
	Where results make sense

Topic: Cetuximab

In the News (Wed 3 Dec 08)

Damian Green

Sumner Redstone

Crimson Tide

Tommy Tuberville

Bill Clinton

Wayne Rooney

Vilasrao Deshmukh

Wake Forest

Grand Slam

Oklahoma State

	MedlinePlus Drug Information: Cetuximab (Systemic) (Site not responding. Last check: 2007-10-14)
		Cetuximab interferes with the growth of cancer cells, which are then eventually destroyed by the body.
		Fibrotic lung disease, pre-existing—May be worsened by cetuximab
		Cetuximab is usually given by a doctor or a nurse in the hospital or an outpatient clinic.
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/500511.html (750 words)

	CETUXIMAB
		Cetuximab combined with cisplatin: cetuximab 100 to 500 milligrams/square meter (mg/m(2)) as a loading dose, then 100 to 250 mg/m(2) weekly for 6 weeks; cisplatin 100 mg/m(2) was given every 3 weeks (cycles could be repeated every 6 weeks based on tolerance/antitumor efficacy) (Shin et al, 2001).
		Cetuximab is approved as monotherapy or in combination with irinotecan for use in patients with epidermal growth factor (EGRF) expressing metastatic colorectal cancer that is refractory/intolerant to irinotecan based chemotherapy.
		Cetuximab is produced by chimerization of M225; specifically, heavy and light chains of the murine antibody are cloned and adapted for expression with constant regions of the human kappa (k) light chain and human gamma-1 heavy chain (Waksal, 1999; Baselga et al, 2000).
	www.micromedex.com /products/updates/drugdex_updates/de/cetuximab.html (4770 words)

	Formulary - Erbitux (Cetuximab) IMCLONE/BRISTOL-MYERS SQUIBB
		Cetuximab, a recombinant, human/mouse chimeric monoclonal antibody, binds specifically to the extracellular domain of EGFR on both normal and tumor cells, thereby inhibiting cell growth and inducing apoptosis.
		Cetuximab was approved on February 12, 2004, in combination with irinotecan for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy.
		Cetuximab was also evaluated in combination with irinotecan in an open-label, single-arm trial (N=138) and as a single agent in another clinical trial (N=57).
	www.formularyjournal.com /formulary/article/articleDetail.jsp?id=87825 (690 words)

	cetuximab - [Medication]
		Cetuximab should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.
		Cetuximab is used in the treatment of cancers of the colon and rectum.
		Cetuximab is in the FDA pregnancy category C. This means that it is not known whether cetuximab will be harmful to an unborn baby.
	www.peacehealth.org /kbase/multum/d05101a1.htm (1112 words)

	Chemotherapy Foundation Symposium and Online Education Program - Mount Sinai School of Medicine (Site not responding. Last check: 2007-10-14)
		Cetuximab (IMC-C225) is a mouse-human chimeric anti-EGFr monoclonal antibody that binds to the receptor with affinity comparable to the natural ligand (12,13).
		Given the correlation of EGFr expression with poor prognosis and the fact that preclinical studies identified Cetuximab as a radiosensitizer, a phase I study was undertaken to assess the interaction of Cetuximab and RT in patients with locally advanced SCCHN.
		Cetuximab serum concentrations were determined using a BIA-core instrument, which measures the binding of antibody in a diluted serum sample to an immobilized source of EGFr in a dextran-coated gold film.
	mssm.edu /tcf/archives/symposiumxviii/abstracts/1109002a_f_abs.shtml (1610 words)

	Cetuximab
		Cetuximab is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR).
		Cetuximab binds to the EGFR on both normal and tumor cells and competitively inhibits the binding of epidermal growth factor and other ligands, such as transforming growth factor-alpha.
		Cetuximab for the treatment of metastatic colorectal carcinoma is considered medically appropriate in combination with irinotecan (e.g., Camptosar®) or as a monotherapy for individuals who are refractory or intolerant to irinotecan based chemotherapy.
	www.bcbst.com /MPManual/Cetuximab.htm (530 words)

	Cetuximab, radiation almost doubles head and neck cancer survival
		Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase 3 study of high dose radiation therapy with or without cetuximab.
		Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck: results of a phase 2 study.
		Phase 1 study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
	www.oralcancerfoundation.org /news/story.asp?newsId=237 (667 words)

	USNews.com: Health: In Brief: Cancer: Drug therapy (10/18/04)
		Cetuximab is an antibody that has been shown in previous studies to enhance the effects of of irinotecan in irinotecan-refractory colorectal cancer.
		Participants on the combination therapy received cetuximab injections every week and also received the same amount of irinotecan that they were given during their most recent treatment before the study.
		Patients on cetuximab monotherapy survived a median of 6.9 months after the start of the study and patients on combination therapy lived somewhat longer—8.6 months was the median lifespan.
	www.usnews.com /usnews/health/briefs/cancer/hb041018b.htm (571 words)

	Cetuximab (Erbitux®) Plus Radiation Boosts Survival for Patients with Head and Neck Cancer
		Cetuximab is a monoclonal antibody that attaches to and blocks EGFRs.
		Patients treated with cetuximab suffered more frequently from a skin rash on the face and body, but this did not appear to reduce the effectiveness of treatment.
		Follow-up studies will be necessary to determine the relative benefit of cetuximab compared to chemotherapy, he adds, and to determine whether combining cetuximab with chemotherapy will provide even greater benefit.
	www.oralcancerfoundation.org /news/story.asp?newsId=667 (452 words)

	Clinical Care Options for Oncology - Cetuximab is active in platinum-refractory recurrent and metastatic squamous cell ...
		A phase 2 multicenter trial demonstrating activity of cetuximab in the treatment of refractory squamous cell cancers of the head and neck (SCCHN) was presented today by José Trigo, MD, at the 40th Annual Meeting of the American Society of Clinical Oncology in New Orleans, Louisiana.
		The current study was designed to evaluate cetuximab's efficacy in patients with stage 3/4 recurrent and/or metastatic SCCHN not suitable as candidates for local therapy, whose disease progressed within 30 days after receipt of 2-6 cycles of platinum-based chemotherapy.
		Cetuximab monotherapy is active in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck.
	clinicalcareoptions.com /onco/news/news_ASCO_5502.asp (489 words)

	Erbitux Online, Description, Chemistry, Ingredients - Cetuximab - RxList Monographs
		ERBITUX is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa.
		ERBITUX is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous, Cetuximab particulates.
		Each single-use, 50-mL vial contains 100 mg of Cetuximab at a concentration of 2 mg/mL and is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.42 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
	www.rxlist.com /cgi/generic3/erbitux.htm (331 words)

	Cetuximab, Erbitux, C225 Chemotherapy Drugs (Site not responding. Last check: 2007-10-14)
		Cetuximab is used to treat metastatic colorectal cancer (cancer spread beyond the colon or rectum) that over-expresses the epidermal growth factor receptor (EGFR).
		Cetuximab is a targeted therapy that targets and binds to the epidermal growth factor receptors (EGFR) on the surface of the cell.
		By binding to these receptors, cetuximab blocks an important pathway that promotes cell division this results in inhibition of cell growth and apoptosis (cell suicide).
	www.chemocare.com /bio/bio.sps?iBiographyID=11555 (1532 words)

	Cetuximab looks promising in colorectal cancer --- HealthandAge (Site not responding. Last check: 2007-10-14)
		They discuss a trial carried out in the UK where cetuximab was added to a standard chemotherapy called irinotecan for patients whose cancer had spread.
		Cetuximab blocks the action of epidermal growth factor which otherwise stimulates the growth of tumor cells.
		It is early days for this new treatment and more clinical trials are needed, but it looks as if it may have at least some benefit for patients whose cancer has spread to other parts of the body.
	www.healthandage.com /Home/gm=1!gid1=6093 (207 words)

	ASCO: Adding Erbitux (Cetuximab) to Radiation Improves Survival in Patients With Head and Neck Cancer (Site not responding. Last check: 2007-10-14)
		In a pilot study of 15 patients with locoregionally advanced head and neck cancers, "all [patients] had a response when radiation was combined with cetuximab, an investigational EGFR blocking antibody," he said.
		There was a significant increase in grade 3/4 infusion reactions in the cetuximab arm (3% vs 0 in the radiation-only arm).
		Cetuximab, marketed as Erbitux, is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing metastatic colorectal cancer who do not tolerate irinotecan-based chemotherapy.
	www.pslgroup.com /dg/2444d2.htm (696 words)

	Cetuximab
		Cetuximab belongs to a group of medications known as monoclonal antibodies.
		Cetuximab is used alone or in combination with other chemotherapy medications to treat metastatic or recurrent colorectal cancer.
		Cetuximab should be administered only under the supervision of a medical oncologist or hematologist.
	my.webmd.com /hw/cancer/tv7826.asp (198 words)

	National Cancer Institute - Cetuximab and Advanced Pancreatic Cancer
		Phase III Randomized Study of Gemcitabine With Versus Without Cetuximab as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas (SWOG-S0205).
		Cetuximab binds to cancer cells and blocks a
		EGFR is found in abnormally high amounts on the surface of many types of cancer cells, causing the cells to divide excessively in the presence of epidermal growth factor proteins.
	cme.nci.nih.gov /clinicaltrials/ft-SWOG-S0205 (266 words)

	Cetuximab detail at IndyaPharma (Site not responding. Last check: 2007-10-14)
		ERBITUX is supplied as a 50-mL, single-use vial containing 100 mg of Cetuximab at a concentration of 2 mg/mL in phosphate buffered saline.
		The solution should be clear and colorless and may contain a small amount of easily visible white amorphous Cetuximab particulates.
		ERBITUX® (Cetuximab) is supplied as a single-use, 50-mL vial containing 100 mg of Cetuximab as a sterile, preservative-free, injectable liquid.
	www.indyapharma.com /Cetuximab-detail.htm (4279 words)

	Colon Cancer Today
		The chemotherapy drug is cetuximab, marketed as Erbitux, which has been approved by the U.S. Food and Drug Administration for use against advanced colorectal cancer that doesn't respond to other treatments.
		The average survival time for the 111 patients in the study who got cetuximab was 6.9 months; for the 218 patients given cetuximab and irinotecan, it was 8.6 months.
		Despite the introduction of cetuximab and other drugs for advanced colorectal cancer, "there is not yet evidence that the new therapies increase cure rates," she said, and the price tag for several months of added life is high.
	www.coloncancertoday.com /ms/news/520199/main.html (657 words)

	Phase I Study of Anti-Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in ...
		Phase I Study of Anti-Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer -- Robert et al.
		Serum levels of cetuximab during therapy shown on a semilogarithmic plot scale at dose levels of (A) 100/100 mg/m
		Cetuximab seems to be a novel biologic modifier, in view
	www.jco.org /cgi/content/full/19/13/3234 (5649 words)

	Cetuximab in Advanced Non-Small Cell Lung Cancer -- Govindan 10 (12): 4241S -- Clinical Cancer Research (Site not responding. Last check: 2007-10-14)
		Cetuximab (C225, Erbitux) is a chimeric monoclonal antibody
		Robert F, Ezekiel MP, Spencer SA, et al Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
		Kelly K, Hanna N, Rosenberg A, Bunn PA, Needle MN multicentered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer.
	clincancerres.aacrjournals.org /cgi/content/full/10/12/4241S (2653 words)

	Clinical Trial: Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage ...
		Determine the feasibility of cetuximab when administered concurrently with paclitaxel, carboplatin, and radiotherapy, in terms of safety and compliance, in patients with unresectable stage IIIA or IIIB non-small cell lung cancer.
		Cetuximab loading dose (week 1): Patients receive a loading dose of cetuximab IV over 2 hours on day 1.
		Concurrent cetuximab and chemoradiotherapy (weeks 2-8): Patients receive cetuximab IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on days 8, 15, 22, 29, 36, 43, and 50.
	clinicaltrials.gov /ct/show/NCT00081302?amp;order=1 (827 words)

	Genesis Health System - Quick Drug Information - Cetuximab
		This medicine may be used by itself, or given with another medicine.
		You should not use this medicine if you have had an allergic reaction to cetuximab.
		Make sure your doctor knows if you have ever had any kind of bad reaction to cetuximab in the past.
	www.genesishealth.com /micromedex/quickdrug/dnx4797.aspx (486 words)

	ASCO: Cetuximab/Irinotecan Combination Slows Progression of Colon Cancer (Site not responding. Last check: 2007-10-14)
		CHICAGO, IL -- June 3, 2003 -- Combination therapy with irinotecan and the monoclonal antibody cetuximab appears to delay tumour progression in patients with refractory metastatic colon cancer, a new study suggests.
		of cetuximab weekly, plus irinotecan at the same dose and schedule on which they had been progressing, or cetuximab alone with the option to switch to the combination of drugs if it failed.
		In patients who received the combination therapy, the most frequent grade 3 and grade 4 toxicities were diarrhoea, experienced by 21.2% of patients, neutropenia in 13.7%, and vomiting in 6.1% of patients.
	www.docguide.com /dg.nsf/PrintPrint/715CAB4DBC11CD8585256D3A0060134A (550 words)

	ASCO - Browse by Meeting - The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor ... (Site not responding. Last check: 2007-10-14)
		The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor.
		Specific inhibitors of EGFR such as the IgG1 anti-EGFR monoclonal antibody cetuximab (Erbitux) have been shown to be active anti-cancer agent in pre-clinical and clinical studies of colorectal tumors.
		The present study indicates that in addition to the ability of cetuximab to block EGFR activation by prevention of ligand binding, it is also inducing degradation of EGFR.
	www.asco.org /ac/1,1003,_12-002636-00_18-0027-00_19-00493,00.asp (808 words)

	Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor ...
		Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry -- Chung et al.
		patients who received cetuximab in a nonstudy setting were identified.
		Cetuximab and Cisplatin for Chemotherapy-Refractory Squamous Cell Cancer of the Head and Neck
	www.jco.org /cgi/content/abstract/23/9/1803 (581 words)

	Lung Cancer Online: Treatment Agents & Regimens: Erbitux (IMC-C225 or cetuximab)
		Erbitux (IMC-C225 or cetuximab) : ImClone/Bristol Myers Squibb : Monoclonal antibody to EGFR
		Abstract of a study presented at the 2003 ASCO annual meeting that found cetuximab in combination is well tolerated and the response rate suggests clinical activity in the second-line setting.
		Press release announcing FDA approval of Erbitux (cetuximab) injection for treatment of some patients with colorectal cancer.
	www.lungcanceronline.org /treatment-agents/E/erbitux.html (135 words)

Try your search on: Qwika (all wikis)